NASDAQ:NTLA - Intellia Therapeutics, Inc.
$13.80
 $-0.09
-0.65%
2:20PM EDT
2019-02-15
Intellia Therapeutics, Inc. is a genome editing company. The Company is focused on developing therapeutics utilizing a biological tool known as CRISPR/Cas9. The CRISPR/Cas9 genome editing system includes two components: the Cas9 protein and the guide RNA sequence. The Cas9 protein acts like a pair of molecular scissors that initiates the natural cellular repair process to knockout, repair or insert a gene. The guide RNA sequence recognizes and directs the Cas9 to a specific target deoxyribonucleic acid (DNA) sequence. The Company's sentinel in vivo programs focus on the use of Lipid Nanoparticle (LNPs) for delivery of the CRISPR/Cas9 complex to the liver. The Company's division, eXtellia Therapeutics, is focused on the application of CRISPR/Cas9 genome editing in the fields of immuno-oncology and autoimmune and inflammatory diseases. The Company's subsidiary is Intellia Securities Corp. As of September 30, 2016, the Company had not generated any revenue. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  NTLA     avg for
industry  
  avg for
sector  
42 stocks weight:  29. 98   0. 00   0. 00  
42 stocks rank:  3. 32 K 1. 86 K 1. 09 K
# analyst opinions:  7. 00   14. 92   14. 43  
mean recommendation:  2. 30   1. 91   1. 93  

quick ratio:  11. 42   5. 37   1. 81  
current ratio:  11. 53   5. 69   2. 19  

target price low:  19. 00   88. 97   117. 82  
target price avg:  24. 19   115. 19   141. 96  
target price high:  39. 79   143. 40   163. 16  
1-yr high:  34. 95   124. 30   142. 77  
last close:  13. 88   101. 85   127. 84  
50-day avg:  14. 30   98. 27   122. 46  
200-day avg:  22. 70   99. 72   122. 70  
1-yr low:  11. 39   78. 19   100. 16  
volume:  1. 04 M 2. 38 M 4. 64 M
50-day avg volume:  576. 58 K 3. 31 M 4. 94 M
200-day avg volume:  709. 73 K 3. 23 M 4. 28 M

1-day return:  0. 95 % 0. 22 % 0. 48 %
this week return:  3. 27 % 1. 77 % 2. 01 %
12-wk return:  -19. 26 % 6. 56 % 3. 33 %
52-wk return:  -47. 75 % -2. 23 % 14. 35 %

enterprise value (EV):  290. 31 M 55. 17 B 104. 51 B
market cap:  602. 69 M 49. 01 B 96. 46 B
EBITDA:  -90. 77 M 4. 82 B 7. 18 B
enterprise multiple (EV/EBITDA):  -3. 20   -91. 79   2. 29  
enterprise/revenue (EV/R):  9. 94   29. 84   23. 39  
total revenue:  29. 22 M 11. 28 B 40. 22 B
total debt:  0. 00   13. 73 B 16. 57 B
net income (common):  -90. 24 M 2. 37 B 3. 58 B

shares outstanding:  43. 42 M 607. 99 M 1. 22 B
shares:  32. 57 M 605. 53 M 1. 15 B
shares short:  7. 41 M 11. 62 M 12. 55 M
shares short prior month:  6. 16 M 11. 95 M 13. 44 M
short ratio:  10. 20   4. 82   3. 10  
short % of float:  18. 50 % 6. 19 % 2. 82 %
total cash/share:  6. 75   12. 02   11. 46  
total cash:  293. 25 M 7. 41 B 7. 37 B
free cash flow:  -40. 97 M 95. 99 M 2. 04 B
operating cash flow:  -74. 03 M 164. 74 M 3. 04 B

book value:  6. 07   14. 43   28. 26  
price/book:  2. 29   -1. 57   -2. 97  
gross profits:  -41. 53 M 8. 28 B 18. 09 B
operating margins:  -324. 55 % -458. 01 % -642. 83 %
EBITDA margins:  0. 00 % 13. 81 % 22. 47 %
profit margins:  0. 00 % 6. 57 % 9. 92 %
gross margins:  -209. 24 % 49. 33 % 54. 53 %

1-yr max volatility:  -16. 98 % --- ---
1-yr mean volatility:  -0. 14 % 0. 01 % 0. 06 %

1-yr EPS:  -2. 16   3. 03   4. 09  
forward EPS:  -2. 52   4. 33   6. 99  
P/E:  -6. 43   6. 11   26. 91  
forward P/E:  -5. 33   8. 38   10. 48  
PE/G:  -5. 36   0. 37   5. 61  
growth:  1. 20 % 683. 72 % 104. 79 %
earnings high:  -0. 34   1. 27   1. 66  
earnings avg:  -0. 54   1. 01   1. 53  
earnings low:  -0. 64   0. 76   1. 40  
revenue high:  18. 50 M 2. 86 B 11. 19 B
revenue avg:  10. 08 M 2. 78 B 10. 84 B
revenue low:  7. 00 M 2. 67 B 10. 64 B
return on assets:  -20. 78 % -3. 27 % 3. 81 %
return on equity:  -41. 10 % 107. 48 % 27. 82 %
revenue growth:  1. 20 % 648. 36 % 97. 70 %
revenue/share:  0. 70   14. 68   59. 83  

beta (1yr vs S&P500):  2. 06   1. 21   0. 93  
sharpe (1yr):  -0. 51   0. 06   0. 98  

held % insiders:  25. 01 % 6. 46 % 3. 21 %
held % institutions:  70. 79 % 79. 10 % 70. 01 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-02-14 : NTLA
.    + 1.568 =         1.568 :: INITIAL WEIGHT
.  + 284.087 =       285.654 :: inverse volume-to-price addition
.  + 358.194 =       643.848 :: spline projection addition
.  - 177.706 =       466.143 :: poor performance penalty
.    x 0.732 =       340.997 :: one-year gains+dividend factor
.    x 3.164 =       1079.03 :: 13 weeks' performance factor
.    x 1.492 =       1610.44 :: industry recommendation factor
.    x 1.634 =       2630.87 :: symbol recommendation factor
.    x 1.333 =      3506.917 :: EV/R factor
.    x 0.998 =      3499.628 :: return on assets factor
.    x 0.996 =      3485.244 :: return on equity factor
.    x 2.194 =      7648.324 :: revenue growth factor
.    x 2.025 =     15489.912 :: current ratio factor
.    x 1.047 =     16215.892 :: quick ratio factor
.    x 1.048 =     16992.206 :: short ratio factor
.    x 2.023 =     34372.965 :: price-to-book factor
.    x 2.135 =     73371.746 :: P/E weight
.    x 0.657 =     48221.383 :: PE/G factor
.    x 1.449 =     69856.151 :: beta factor
.    x 0.506 =     35363.596 :: sharpe factor
.    x 1.642 =     58079.696 :: target low factor
.    x 1.287 =     74766.392 :: target mean factor
.    x 1.137 =     84981.558 :: target high factor
.    x 1.066 =     90557.436 :: industry 12-weeks return
.    x 0.987 =     89338.302 :: "drift" penalty 1 days ago
.    x 0.996 =     89008.557 :: overall "drift" factor
.    x 0.999 =     88945.311 :: largest single-day jump factor
.    x 0.303 =     26953.125 :: low price factor
.      x 1.0 =     26954.934 :: factor hist industry gain for week 06
.   cubeRoot =        29.983 :: reduced for readability
.                     29.983 :: FINAL WEIGHT for NASDAQ:NTLA


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org